Summit Therapeutics is trading at approximately $12.45 (5% down), extending a multi-day slide after its July 23, 2026, earnings update shifted investor focus toward ivonescimab launch spending and elevated R&D guidance.
- The downward move persists despite a strong backdrop in the broader biotech sector, suggesting the market is continuing to digest the company's heavy 2026 investment plans.
- Sentiment appears driven by a reassessment of near-term capital requirements and upcoming PDUFA regulatory risks rather than fresh company-specific news this morning.